IVVD · Invivyd, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on current operating plans and excluding future external financing, we will not have sufficient cash and cash equivalents to fund our operating expenses and capital requirements beyond one year from the issuance date of the condensed consolidated financial statements in this Quarterly Report on Form 10-Q, and therefore, we have concluded that there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| PEMGARDA net product revenue | $14.3M | Q2 2026 | +21.3% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IVVD
this stock
Invivyd, Inc.
|
$212.49M | -70.8% | +110.5% | — | 9.4% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IVVD | -2.6% | -3.0% | -55.2% | +34.8% | -70.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -3.0% | -7.4% | -69.0% | +30.8% | -84.7% |